Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang-Lin Yang

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Bioorganic Chemistry|April 17, 2023
Abietane diterpenoids from Orthosiphon wulfenioides with NLRP3 inflammasome inhibitory activityWen-Chao Tu, Ying-Xin Zhao, Chang-Lin Yang, et al.
Frontiers in Immunology|February 16, 2026
M2 macrophage-based classification identifies DOK3 as a driver of pro-tumoral polarization and migration in glioblastomaChang-Yuan Ren, Ji Shi, Chang-Lin Yang, et al.
Nucleic Acids Research|October 28, 2023
circRNADisease v2.0: an updated resource for high-quality experimentally supported circRNA-disease associationsZhi-Yan Sun, Chang-Lin Yang, Li-Jie Huang, et al.
Chinese Medical Journal|September 14, 2020
Impact of metabolic syndrome on short-term outcome of carotid revascularization: a large sample size study in Chinese populationXue-Song Bai, Yao Feng, Tao Wang, et al.
Plos One|February 6, 2014
Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in ChinaFeng-Cai Zhu, Shou-Jie Huang, Ting Wu, et al.
Human Vaccines & Immunotherapeutics|July 27, 2013
Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adultsTing Wu, Shou-Jie Huang, Feng-Cai Zhu, et al.
Human Vaccines & Immunotherapeutics|October 29, 2013
Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trialYue-Mei Hu, Shou-Jie Huang, Kai Chu, et al.
Vaccine|June 24, 2015
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trialTing Wu, Yue-Mei Hu, Juan Li, et al.
Lancet (London, England)|August 24, 2010
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trialFeng-Cai Zhu, Jun Zhang, Xue-Feng Zhang, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Safety and immunogenicity of an Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Bioorganic Chemistry|April 17, 2023
Abietane diterpenoids from Orthosiphon wulfenioides with NLRP3 inflammasome inhibitory activityWen-Chao Tu, Ying-Xin Zhao, Chang-Lin Yang, et al.
Frontiers in Immunology|February 16, 2026
M2 macrophage-based classification identifies DOK3 as a driver of pro-tumoral polarization and migration in glioblastomaChang-Yuan Ren, Ji Shi, Chang-Lin Yang, et al.
Nucleic Acids Research|October 28, 2023
circRNADisease v2.0: an updated resource for high-quality experimentally supported circRNA-disease associationsZhi-Yan Sun, Chang-Lin Yang, Li-Jie Huang, et al.
Chinese Medical Journal|September 14, 2020
Impact of metabolic syndrome on short-term outcome of carotid revascularization: a large sample size study in Chinese populationXue-Song Bai, Yao Feng, Tao Wang, et al.
Plos One|February 6, 2014
Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in ChinaFeng-Cai Zhu, Shou-Jie Huang, Ting Wu, et al.
Human Vaccines & Immunotherapeutics|July 27, 2013
Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adultsTing Wu, Shou-Jie Huang, Feng-Cai Zhu, et al.
Human Vaccines & Immunotherapeutics|October 29, 2013
Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trialYue-Mei Hu, Shou-Jie Huang, Kai Chu, et al.
Vaccine|June 24, 2015
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trialTing Wu, Yue-Mei Hu, Juan Li, et al.
Lancet (London, England)|August 24, 2010
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trialFeng-Cai Zhu, Jun Zhang, Xue-Feng Zhang, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
Safety and immunogenicity of an Kai Chu, Zhao-Feng Bi, Wei-Jin Huang, et al.
Pageof 3